Clinical Trials Directory

Trials / Sponsors / KalVista Pharmaceuticals, Ltd.

KalVista Pharmaceuticals, Ltd.

Industry · 14 registered clinical trials.

StatusTrialPhaseStarted
CompletedA Study Observing US Patients With HAE Type I or II Who Take Icatibant to Treat HAE Attacks
Hereditary Angioedema
—2025-04-21
CompletedOpen-Label Safety, PK, and Efficacy Trial of Sebetralstat (KVD900) in Pediatric Patients (Ages 2-11) With HAE
Hereditary Angioedema
Phase 32024-06-24
Active Not RecruitingPK Subtrial in Adolescent Patients With HAE Type I or II Participating in the KVD900-302 Trial
Hereditary Angioedema
Phase 32022-10-24
Active Not RecruitingAn Open-label Extension Trial to Evaluate the Long-term Safety of KVD900 (Sebetralstat) for On-Demand Treatmen
Hereditary Angioedema
Phase 32022-10-24
CompletedA Phase III, Crossover Trial Evaluating the Efficacy and Safety of KVD900 (Sebetralstat) for On-Demand Treatme
Hereditary Angioedema
Phase 32022-02-22
TerminatedA Trial to Evaluate the Efficacy and Safety of Different Doses of KVD824 for Prophylactic Treatment of HAE Typ
Angioedema, Hereditary, Types I and II
Phase 22021-09-27
CompletedPhase 1 Crossover Study in Healthy Subjects to Evaluate the PK Profile of KVD824 Following Single and Multiple
Hereditary Angioedema
Phase 12020-05-19
CompletedA Phase II, Cross-over Clinical Trial Evaluating the Efficacy and Safety of KVD900 (Sebetralstat) in the On-de
Hereditary Angioedema
Phase 22019-07-02
CompletedA Single and Multiple Doses Safety, Tolerability, Pharmacokinetics and Food Effect Study of KVD824 in Healthy
Hereditary Angioedema
Phase 12019-02-12
CompletedStudy of the Intravitreal Plasma Kallikrein Inhibitor, KVD001, in Subjects With Center-involving Diabetic Macu
Diabetic Macular Edema
Phase 22018-02-16
CompletedA Single Dose Safety, Tolerability, Pharmacokinetic and Food Effect Study of KVD900 (Sebetralstat) in Healthy
Hereditary Angioedema
Phase 12018-01-04
CompletedA Phase I Single Ascending Dose Study of the Intravitreal Plasma Kallikrein Inhibitor KVD001 in Subjects With
Diabetic Macular Edema
Phase 12014-07-18
Approved For MarketingTreatment of Angioedema Attacks in Adolescent and Adult Patients 12 Years and Older With HAE Type I or II With
Hereditary Angioedema
——
AvailableTreatment of Angioedema Attacks in Pediatric (Ages 2-11) Post-Trial and Naive Patients With HAE With Sebetrals
Hereditary Angioedema
——